NCT00340717|Completed
Markers for Early Detection of Prostate Cancer
Multi-Institutional Pilot Study to Evaluate Molecular Markers in Urine and Serum in the Early Detection of Prostate Cancer
Loading search results
Multi-Institutional Pilot Study to Evaluate Molecular Markers in Urine and Serum in the Early Detection of Prostate Cancer
Sponsor study identifier
Secondary identifiers
observational
100
1 country
1
Study Start
May 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedThis study will determine whether certain gene alterations can serve as markers for early detection of prostate cancer. Prostate cancer is often diagnosed by detecting high levels of a protein called prostate-specific antigen (PSA) in the blood. Other conditions can also cause elevated PSA levels, however, so that additional tests are needed to distinguish between benign and cancerous prostate conditions. Patients between 40 and 75 years of age who are referred to Howard University Hospital in Washington, D.C., or Madigan Army Medical Center in Tacoma, Washington, for ultrasound and needle biopsy to diagnose prostate cancer may be eligible for this study. Participants will undergo the following procedures at the time of the biopsy visit:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2003
Date type not reportedThis date has not been verified as actual or estimated.
June 19, 2006
Actual (reported)June 21, 2006
Actual (reported)Madigan Army Medical Center
Tacoma, Washington, 98431, United States
Orozco R, O'Dowd G, Kunnel B, Miller MC, Veltri RW. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology. 1998 Feb;51(2):186-95. doi: 10.1016/s0090-4295(97)00620-1.
First Submitted
June 19, 2006
First Posted
June 21, 2006
Study Start
May 2003
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
March 4, 2008
Record last verified: 2006-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
Contact the study team to confirm eligibility.